CHU Clermont-Ferrand
Clermont-Ferrand, 63003, France
NCT Number: NCT02042612
Describing a pharmacokinetic model of 48-h sevoflurane sedation in obese ICU patients
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Clermont-Ferrand, 63003, France
Prospective clinical monocentric study in ICU with sedated ventilated obese patients with sevoflurane during 48 h with the AnaConda® system, establishing pharmacokinetic model of sévoflurane and its metabolites (hydroxyfluroisopropanol, fluoride)
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Determination of plasmatic concentrations of sevoflurane at different times of a 48h sedation of sevoflurane in obese ICU patients
Time frame: at 5min, 60 min, 24 hrs and just before the end of sedation.
Time frame: at 5min, 60 min, 24 hrs and just before the end of sedation.
University Hospital, Clermont-Ferrand
Other
Acronym: CISEVOB
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05742165
Behavior, Body Weight
New York, United States
View Trial DetailsNCT05882045
Body Weight, Cardiovascular Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT05929079
Apnea, Body Weight
Anniston, Alabama, United States
View Trial DetailsNCT00342732
Body Weight, Nutrition Disorders
Phoenix, Arizona, United States
View Trial Details